Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

813
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
813
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

801
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
801
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

786
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
786
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

643
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
643
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

936
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
936
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

2.7K
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Derivation and validation of a prediction model for long-term mortality in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the PREDICT-ST-Elevation Myocardial Infarction score.

Heart (British Cardiac Society)·2026
Same author

Malnutrition and mortality in patients≥75 years with chronic heart failure.

Medicina clinica·2026
Same author

Preoperative Use of Venoarterial Extracorporeal Membrane Oxygenation in Postinfarct Ventricular Septal Rupture: Insights From the Extracorporeal Life Support Organization Registry.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Characteristics, management, and prognosis of out-of-hospital cardiac arrest of cardiac cause according to the treating center.

Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias·2026
Same author

Age-based analysis of the SEC-Excelente-HF registry: clinical characteristics and prognosis of a prospective cohort of heart failure patients.

European geriatric medicine·2025
Same author

Correction: Socioeconomic status and equity among patients with cardiogenic shock.

Frontiers in cardiovascular medicine·2025

Related Experiment Video

Updated: Apr 27, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.3K

Anthracycline-mediated cardiomyopathy: basic molecular knowledge for the cardiologist.

Joel Salazar-Mendiguchía1, José González-Costello1, Josep Roca1

  • 1Unidad de Miocardiopatías, Insuficiencia Cardíaca y Trasplante, Área de Enfermedades del Corazón, Hospital Universitari de Bellvitge, Barcelona, Spain.

Archivos De Cardiologia De Mexico
|July 9, 2014
PubMed
Summary
This summary is machine-generated.

Anthracyclines like doxorubicin are vital cancer drugs, but cause heart damage. New research reveals multiple toxicity mechanisms beyond oxidative stress, aiding better patient care.

Keywords:
Anthracycline cardiotoxicityCardiotoxicidad de antraciclinasChemotherapy cardiomyopathyDoxorubicin cardiomyopathyEspañaMiocardiopatía por doxorrubicinaMiocardiopatía por quimioterapiaSpain

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.2K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

6.9K

Related Experiment Videos

Last Updated: Apr 27, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.3K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.2K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

6.9K

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Anthracyclines are widely used antineoplastic drugs that inhibit topoisomerase II.
  • Doxorubicin and daunorubicin are key examples, but their use is limited by cardiotoxicity.
  • Improved cancer survival leads to increased incidence of chemotherapy-induced cardiotoxicity.

Purpose of the Study:

  • To review the diverse mechanisms underlying anthracycline cardiotoxicity.
  • To highlight factors beyond reactive oxygen species (ROS) in cardiotoxicity.
  • To emphasize the importance of understanding these mechanisms for clinical practice.

Main Methods:

  • Review of existing literature on anthracycline cardiotoxicity.
  • Analysis of mechanisms including sarcomeric disruption, metabolite accumulation, iron metabolism, energy alterations, and inflammation.
  • Exploration of the role of genetics in cardiotoxicity.

Main Results:

  • Cardiotoxicity is multifactorial, with no single mechanism fully explaining the clinical presentation.
  • Factors such as sarcomeric disruption, toxic metabolite buildup, altered iron metabolism, and inflammation are significant contributors alongside ROS.
  • The genetic basis of cardiotoxicity requires further elucidation.

Conclusions:

  • Anthracycline cardiotoxicity involves complex, interconnected pathways.
  • A comprehensive understanding of these mechanisms is crucial for managing cardiotoxicity in cancer patients.
  • This knowledge is vital for cardiologists facing challenges with current and future anticancer therapies.